---
document_datetime: 2024-10-11 16:18:45
document_pages: 14
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lojuxta-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: lojuxta-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 8.5148122
conversion_datetime: 2025-12-17 14:02:04.969188
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Lojuxta

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IA/0062/G            | This was an application for a group of variations.                                                                                                                                                                                                             | 02/09/2024                          | n/a                                         |                                  |           |
|                      | A.7 - Administrative change - Deletion of manufacturing sites A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) |                                     |                                             |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| T/0060              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                       | 12/07/2024   | 05/08/2024   | SmPC, Labelling and PL   |                                                                                                                                                                                                                                                                       |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10112 /202307 | Periodic Safety Update EU Single assessment - lomitapide                                                                                                                                                                                                                                                  | 07/03/2024   | n/a          |                          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                     |
| S/0057              | Annual re-assessment.                                                                                                                                                                                                                                                                                     | 22/02/2024   | n/a          |                          |                                                                                                                                                                                                                                                                       |
| N/0058              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                          | 12/10/2023   | 10/05/2024   | PL                       |                                                                                                                                                                                                                                                                       |
| IB/0056             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                              | 26/07/2023   | n/a          |                          |                                                                                                                                                                                                                                                                       |
| R/0054              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                   | 30/03/2023   | 26/05/2023   | SmPC                     | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Lojuxta in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IAIN/0055/G         | This was an application for a group of variations. B.II.c.3.z - Change in source of an excipient or reagent with TSE risk - Other variation B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.b.2.c.1 - Change to importer, batch release | 05/05/2023   | 10/05/2024   | Annex II and PL          |                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                     | arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                          |            |            |                            |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------|-----------------------------------|
| PSUSA/10112 /202207 | Periodic Safety Update EU Single assessment - lomitapide                                                                                                                                                                                                                                       | 16/03/2023 | n/a        |                            | PRAC Recommendation - maintenance |
| S/0052              | Annual re-assessment.                                                                                                                                                                                                                                                                          | 15/12/2022 | n/a        |                            |                                   |
| IB/0051             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                         | 08/08/2022 | n/a        |                            |                                   |
| PSUSA/10112 /202107 | Periodic Safety Update EU Single assessment - lomitapide                                                                                                                                                                                                                                       | 10/03/2022 | n/a        |                            | PRAC Recommendation - maintenance |
| S/0048              | Annual re-assessment.                                                                                                                                                                                                                                                                          | 24/02/2022 | n/a        |                            |                                   |
| II/0046             | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 24/02/2022 | 13/01/2023 | Annex II, Labelling and PL |                                   |
| IA/0050             | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                               | 08/11/2021 | n/a        |                            |                                   |

<div style=\"page-break-after: always\"></div>

| II/0047             | Introduction of an enhanced pharmacovigilance system to evaluate the occurrence and outcomes of pregnancy in females of reproductive potential treated with lomitapide who decide to continue the pregnancy following advice from a teratologist/clinician, replacing the currently agreed Pregnancy Exposure Register (PER), which is listed as part of the specific obligations in the Annex II. The RMP version 6.5 has also been submitted. In addition, the MAH took the opportunity to introduce minor administrative changes. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH   | 28/10/2021   | 03/12/2021   | Annex II               | Annex II E is being amended to delete the Pregnancy exposure registry, which is being replaced by an updated Pharmacovigilance system, which introduces also congenital anomalies as an outcome of primary interest.                                             |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10112 /202007 | Periodic Safety Update EU Single assessment - lomitapide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 11/03/2021   | n/a          |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                |
| S/0043              | 7th annual re-assessment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 28/01/2021   | n/a          |                        | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Lojuxta should be maintained. |
| IAIN/0045           | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 07/12/2020   | 03/12/2021   | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| IA/0042             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                         | 21/08/2020   | n/a        |                 |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-----------------------------------|
| IA/0041/G           | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of | 04/08/2020   | n/a        |                 |                                   |
| S/0036              | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 26/03/2020   | n/a        |                 |                                   |
| PSUSA/10112 /201907 | Periodic Safety Update EU Single assessment - lomitapide                                                                                                                                                                                                                                                                                                                                                                                                              | 13/02/2020   | n/a        |                 | PRAC Recommendation - maintenance |
| IA/0040/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                            | 23/01/2020   | 09/03/2020 | Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |     |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0039/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or | 11/12/2019 | n/a |

<div style=\"page-break-after: always\"></div>

|           | Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material)           |            |     |           |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| IA/0038/G | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test | 27/11/2019 | n/a | procedure |

<div style=\"page-break-after: always\"></div>

| IAIN/0035           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                       | 11/04/2019   | n/a        |                        |                                                                                                                                                                                                                                                                                                  |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0034/G         | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 11/04/2019   | 09/03/2020 | Annex II and PL        |                                                                                                                                                                                                                                                                                                  |
| PSUSA/10112 /201807 | Periodic Safety Update EU Single assessment - lomitapide                                                                                                                                                                                                                                                                                                                                     | 14/02/2019   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                |
| S/0032              | 5th annual re-assessment                                                                                                                                                                                                                                                                                                                                                                     | 31/01/2019   | n/a        |                        | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that Marketing Authorisation under exceptional circumstances of Lojuxta should be maintained. |
| T/0031              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                          | 27/07/2018   | 27/08/2018 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                  |
| IB/0030             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale                                                                                                                                                                                                                                                                                  | 14/06/2018   | 27/08/2018 | SmPC                   |                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|                     | (supported by real time data)                                                                                                                                                                                                                                |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0029              | Renewal of the marketing authorisation.                                                                                                                                                                                                                      | 22/02/2018 | 23/04/2018 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Lojuxta in the approved indication remains favourable, but recommended that one additional five-year renewal be required based on the following pharmacovigilance grounds: - Lojuxta was granted a Marketing Authorisation under exceptional circumstances and the MAH committed to complete a number of post-approval commitments within agreed timeframes. One specific obligation is still pending, due to the fact that two registries (LOWER and PER) are still ongoing, which will generate further clinical (safety and effectiveness) data. - Further, considering the safety profile of Lojuxta, the MAH was requested to continue to submit yearly PSURs unless otherwise specified. |
| II/0028             | B.I.a.1.g - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new manufacturer of the AS that is not supported by an ASMF and requires significant update to the relevant AS section in the dossier | 15/03/2018 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| PSUSA/10112 /201707 | Periodic Safety Update EU Single assessment - lomitapide                                                                                                                                                                                                     | 08/02/2018 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| S/0026              | 4th annual re-assessment                                                                                                                                                                                                                                     | 25/01/2018 | n/a        |                                  | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                          |            |            |                                  | of Lojuxta should be maintained.                                                                                                                                                                                                                                 |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0023              | 3th Annual Re-assessment                                                                                                                                                                                 | 23/03/2017 | n/a        |                                  | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that Marketing Authorisation of Lojuxta should be maintained. |
| N/0025              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                         | 17/03/2017 | 23/04/2018 | PL                               |                                                                                                                                                                                                                                                                  |
| PSUSA/10112 /201607 | Periodic Safety Update EU Single assessment - lomitapide                                                                                                                                                 | 09/02/2017 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                |
| PSUSA/10112 /201601 | Periodic Safety Update EU Single assessment - lomitapide                                                                                                                                                 | 15/09/2016 | 11/11/2016 | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10112/201601.                                                                                                                       |
| X/0016              | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                               | 17/12/2015 | 18/02/2016 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                  |
| PSUSA/10112 /201507 | Periodic Safety Update EU Single assessment - lomitapide                                                                                                                                                 | 11/02/2016 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                |
| S/0020              | Annual re-assessment.                                                                                                                                                                                    | 19/11/2015 | n/a        |                                  |                                                                                                                                                                                                                                                                  |
| PSUSA/10112 /201501 | Periodic Safety Update EU Single assessment - lomitapide                                                                                                                                                 | 10/09/2015 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                |
| IA/0019             | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where | 21/08/2015 | n/a        |                                  |                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|           | batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |             |                                                                                                                                                                                                                                                         |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0018   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 22/07/2015 | 18/02/2016 | Annex II    |                                                                                                                                                                                                                                                         |
| IA/0017   | B.II.e.4.a - Change in shape or dimensions of the container or closure (immediate packaging) - Non- sterile medicinal products                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 23/06/2015 | n/a        |             |                                                                                                                                                                                                                                                         |
| II/0014/G | This was an application for a group of variations. Grouping of three type II variations as follows: Variation 1 Submission of the CSR for study AEGR-733-024 undertaken to investigate the effect of atorvastatin (a weak CYP3A4 inhibitor) on the pharmacokinetics of lomitapide; Variation 2 Submission of the CSR for study AEGR-733-029 undertaken to investigate the effect of Ortho Cyclen (ethinyl estradiol/norgestimate; a weak CYP3A4 inhibitor) on the pharmacokinetics of lomitapide; Variation 3 Submission of the final report related to the validation of a mechanistic (PBPK) model to predict lomitapide interactions with CYP3A4 inhibitors. As a consequence sections 4.2, 4.4 and 4.5 of the SmPC have been updated and the Package Leaflet and the RMP have been updated accordingly. A | 26/02/2015 | 30/03/2015 | SmPC and PL | Data from three drug-drug interaction studies and from literature on effect of CYP3A4 inhibitors have been analysed and justify the recommendation for concomitant dosing separation and adjustment of lomitapide when combined with CYP3A4 inhibitors. |

<div style=\"page-break-after: always\"></div>

|                     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |             |                                                                                                                                                                                                                                                                      |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10112 /201407 | Periodic Safety Update EU Single assessment - lomitapide                                                                                                                                                                                                                                                                                                | 12/02/2015 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                    |
| II/0012             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                           | 18/12/2014 | n/a        |             |                                                                                                                                                                                                                                                                      |
| S/0011              | First Annual Re-assessment                                                                                                                                                                                                                                                                                                                              | 20/11/2014 | n/a        |             | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that the Marketing Authorisation of Lojuxta should be maintained. |
| PSUV/0008           | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                  | 25/09/2014 | 19/11/2014 | SmPC and PL | Please refer to Lojuxta-EMEA-H-C-2578-PSUV-0008 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation.                                                                                                     |
| IAIN/0010           | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                         | 27/06/2014 | n/a        |             |                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| IB/0007   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 06/06/2014   | n/a        |                  |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------|
| N/0009    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 03/06/2014   | 19/11/2014 | Labelling and PL |
| IA/0006/G | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative | 28/02/2014   | 19/11/2014 | SmPC             |
| II/0004   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 23/01/2014   | n/a        |                  |
| IB/0003   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 10/01/2014   | n/a        |                  |

<div style=\"page-break-after: always\"></div>

| T/0002    | Transfer of Marketing Authorisation                | 22/11/2013   | 18/12/2013   | SmPC, Labelling and PL   |
|-----------|----------------------------------------------------|--------------|--------------|--------------------------|
| IB/0001/G | This was an application for a group of variations. | 16/09/2013   | n/a          |                          |